Atlas Trials

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Clinical trial NCT02168140 · COMPLETED

Trial details

NCT number
NCT02168140
Sponsor
Wake Forest University Health Sciences
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Adult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin LymphomaAdult Nasal Type Extranodal NK/T-cell LymphomaAdult Nodular Sclerosis Hodgkin LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaHepatosplenic T-cell LymphomaNoncutaneous Extranodal LymphomaPeripheral T-cell LymphomaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Hodgkin Lymphoma
Start date
2014-09-01
Primary completion
2019-04-18
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.